Biogen stumbles in crucial ALS study
![Brian Snyder/Reuters/Ritzau Scanpix | Photo: Brian Snyder/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13378564.ece/ALTERNATES/schema-16_9/20211018-011958-3-1920x1920we.jpg)
US-based biotech company Biogen has not managed to attain its primary endpoint goal in a crucial phase III study of its canditate tofersen, also called BIIB067, as a treatment for a specific type of ALS, SOD1-ALS, the firm reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.